Can a drug slow kidney loss in inherited cystic disease?
NCT ID NCT02127437
First seen Apr 18, 2026 · Last updated May 12, 2026 · Updated 4 times
Summary
This study tested whether lanreotide, a drug that affects certain hormones, can slow the loss of kidney function in people with autosomal dominant polycystic kidney disease (ADPKD). The trial included 159 adults with moderate kidney damage and measured their kidney function over three years. The goal was to see if lanreotide could reduce the rate of decline by at least 30% compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Necker hospital
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.